Stay tuned and follow the latest developments and news in Molecular Oncology.
There are rapid developments in the field of early diagnosis of many cancers. Pioneering molecular tests, which also use AI, are now available in our country and can change the landscape of early diagnosis.
Τhe topic was the focus of the 8th annual Health Innovation Conference, which discussed the latest developments in AI in healthcare. As reported, a molecular test that is performed in the blood and detects 15 types of cancer, such as lung cancer, early with up to 99% accuracy was recently approved by the FDA.
About colorectal cancer, Colon AiQ test has recently become available in Greece. It is based on molecular biology and artificial intelligence and detects colorectal cancer accurately in very early stages with a simple blood draw!
“Colorectal cancer is one of the most deadly cancers in America and Europe due to reduced screening as many people avoid colonoscopy. New early detection methods are coming to change the rates of people who go for screening, hence the rates of early diagnosis,” noted molecular biologist Nikos Tsoulos, CEO of Genekor Medical SA.
It is worth noting that if colorectal cancer is diagnosed at an early stage (stage I or II) then the five-year survival rate is up to 90%. On the contrary, if the tumour is diagnosed in an advanced stage (stage 4), the corresponding rate is only 10%!
According to the World Health Organisation, early diagnosis brings significant benefits to patients and 2-4 times greater savings for health systems. The aim is to increase the percentage of people who are screened for cancer by offering, non-invasive and reliable tests.
Another cancer with a mortality rate of more than 95% is pancreatic cancer, which until now has not been screened for and is usually diagnosed at very advanced stages. The Avantect molecular blood test, can detect pancreatic cancer with high accuracy and is recommended for people with a family history or type 2 diabetes and over 50 years of age, who have a 6-8 times higher risk of developing this cancer.
The Avantect molecular blood test can detect pancreatic cancer with high accuracy and is recommended for people with a family history or type 2 diabetes and over 50 years of age, who have a 6-8 times higher risk of developing this cancer.